See every side of every news story
Get Started
SubscribeLogin
Pope Francis
Basketball
Vatican
Wrestling
MLS
Baseball
Donald Trump
Hockey
Tennis
Israel-Hamas Conflict
Hamas
Ukraine War
Published • loading... • Updated

Fragile X syndrome market to quadruple to $111.9 million in US and Germany by 2030, forecasts GlobalData - GlobalData

Summary by GlobalData
The fragile X syndrome (FXS) market across the US and Germany is projected to experience explosive growth, quadrupling from $28.7 million in 2025 to $111.9 million by 2030, a CAGR of 31.3% (2025-2030), driven by the anticipated launch of two high-priced targeted therapies for FXS in 2027, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, “Fragile X Syndrome: Opportunity Assessment and Forecast -Update,” a…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
Express PharmaExpress Pharma

Fragile X syndrome market to quadruple to $111.9 million in US and Germany by 2030, forecasts GlobalData - Express Pharma

The fragile X syndrome (FXS) market across the US and Germany is projected to experience explosive growth, quadrupling from $28.7 million in 2025 to $111.9 million by 2030, a CAGR of 31.3 per cent (2025-2030), driven by the anticipated launch of two high-priced targeted therapies for FXS in 2027, according to GlobalData. GlobalData’s latest report, “Fragile X Syndrome: Opportunity Assessment and Forecast -Update,” anticipates a stable market unt…

Read Full Article
GlobalDataGlobalData

Fragile X syndrome market to quadruple to $111.9 million in US and Germany by 2030, forecasts GlobalData - GlobalData

The fragile X syndrome (FXS) market across the US and Germany is projected to experience explosive growth, quadrupling from $28.7 million in 2025 to $111.9 million by 2030, a CAGR of 31.3% (2025-2030), driven by the anticipated launch of two high-priced targeted therapies for FXS in 2027, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, “Fragile X Syndrome: Opportunity Assessment and Forecast -Update,” a…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

GlobalData broke the news in on Tuesday, February 18, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States

United States

News
For You
Search
BlindspotLocal